Overview

A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2028-03-31

Target enrollment:

Participant gender:

Summary

This study is PhaseⅠstudy to examine tolerability and safety of ONO-7475 in combination with ONO-4538 and gemcitabine plus nab-paclitaxel (GnP), the standard of care, and safety of ONO-7475 in combination with GnP in patients with metastatic pancreatic cancer as first-line treatment

Phase:

PHASE1

Details

Lead Sponsor:

Ono Pharmaceutical Co. Ltd

Treatments:

130-nm albumin-bound paclitaxel
Gemcitabine
Nivolumab